Bausch & Lomb Ophthalmic ZyLET Is “Approvable” At FDA

The company expects to launch the anti-inflammatory/antibiotic agent Zylet by year-end. Bausch & Lomb acquired rights to the loteprednol ophthalmic business from Pharmos.